Overview
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Eligibility
Inclusion Criteria:
- ≥18 years of age
- Physician-reported diagnosis of moderate to severe plaque psoriasis
- Be newly initiating deucravacitinib
- Do not object to participate
Exclusion Criteria:
- Currently participating in or planning to participate in an interventional clinical trial
- Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial